A Phase 1, Open-label, Single-center Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Oct 2016
At a glance
- Drugs Iberdomide (Primary) ; Itraconazole; Rifampicin
- Indications Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 17 Oct 2016 Status changed from recruiting to completed.
- 12 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Sep 2016.
- 12 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Sep 2016.